Chi Podcasts

Dr. Edward Patz outlines what he considers some of the greatest obstacles to developing novel antibodies from single human B cells, how he recognized a novel and unexpected target in lung cancer, the current status of the first novel antibody he developed, advice for people introducing novel antibody therapeutics in the clinical setting and exciting new developments emerging for antibodies derived from single human B cells.

Genomics analyses have become much more affordable over the recent years. Creating a growth that makes the Life Science market projected to be worth 20 Billion US Dollars by 2020. In fact, research centers and hospitals specialized in the fields of Bio IT, Sequencing and other Life Sciences have acquired the latest technologies for their applications. As the demand for genomics analyses grows, these organizations are constantly creating new and more digital information. Therefore, IT managers are confronted with the impact of Big Data and must improve their IT infrastructure to respond to the needs of their workflows. Mr. Steven Rietveld, of NODEUM, will introduce this market and its related challenges during this podcast.

Scott Hopes and John Chuang recently sat down with CHI to discuss their upcoming presentation at Medical Informatics World. They discuss reimbursement issues and possible solutions to overcome regulatory hurdles to make telehealth a viable and affordable care option. For more information, please visit http://www.MedicalInformaticsWorld.com/Telehealth/

Mohammad F. Kiani of Temple University speaks to Cambridge Healthtech Institute on March 9, 2017. He will be a presenter during the 3D Cellular Models conference at World Preclinical Congress, June 12-16 in Boston, Massachusetts. For more information, please visit http://www.WorldPreclinicalCongress.com/3D-Cellular-Models/

A podcast interview with PEGS speaker David Weis of the University of Kansas. Dr. Weis is speaking in the Biophysical Analysis of Biotherapeutics meeting, where he will give a presentation on the topic “Hydrogen Exchange Mass Spectrometry in Formulation Development and Similarity Assessment”

Liz Worthey of HudsonAlpha Institute for Biotechnology speaks to Cambridge Healthtech Institute on March 9, 2017. She will be a featured presenter during a shared session for the Clinical Genomics and Data Security conferences at Bio-IT World Conference & Expo, May 23-25 in Boston, Massachusetts. For more information, please visit http://www.Bio-ITworldExpo.com/

Tom Lawler, Founder & Managing Partner, BaywynSolutions spoke to CHI to discuss the role of teamwork in outsourcing relationships for clinical trials and some of the tangible challenges, delays, and errors that can come from teams lacking a collaborative framework. He also discusses some metrics groups can use to measure their success in their outsourced relationships. Tom is speaking at Outsourcing for Clinical Trials, taking place April 25-26, 2017 in Boston as part of the Clinical Trial Innovation Summit. For details, visit: http://www.ClinicalTrialSummit.com/Clinical-Outsourcing/

Dr. Thomas Kleen outlines some of the challenges biomarker discovery, discusses his role in the STIC/FDA Immunotherapy Biomarkers Taskforce, and the focus of his work at Epiontis as the Executive Vice President of Immune Monitoring in this podcast for the Biomarkers for Immunotherapy conference at Molecular Diagnostics Europe Summit. To learn more, please visit http://www.MolecularDXEurope.com/Immunotherapy-Biomarkers/

Vatche Kalfayan, Senior Director, Clinical Operations, Pfizer spoke to CHI to discuss the lessons learned about outsourcing for clinical trials from his experience working in pharma and founding a CRO. He discusses the biggest challenges clinical trial professionals are facing in their outsourcing models and strategies, as well as some examples of how the field is changing and what he’s working on to drive some of that change. Vatche is speaking at Outsourcing for Clinical Trials, taking place April 25-26, 2017 in Boston as part of the Clinical Trial Innovation Summit. For details, visit: http://www.ClinicalTrialSummit.com

Biotherapeutic drugs such as monoclonal antibodies (mAbs) have the potential to induce immunogenicity; therefore, it is critical to perform an immunogenicity assessment to ensure drug efficacy and patient safety. In general, an immunogenicity assessment is performed in a multi-tiered approach: screening of anti-drug antibodies (ADA), confirmatory test, titer assessment, characterization of ADA for neutralizing drug activity and isotyping. The goal of our work is to develop multiplex approaches on various platforms including Meso Scale Discovery (MSD), Luminex and Delfia for ADA characterization. To learn more, please visit http://www.PEGSummit.com/Immunogenicity/

Mike Elliott, of Atrium Consulting, discusses the current problems and challenges facing IT. He talks about how IT needs to move into a more visible space in the future, and begin taking a more proactive rather than reactive stance. For more information, please visit http://www.Bio-ITWorldExpo.com

Peter Emtage from Cell Design Labs recently spoke with CHI. He will be speaking at PEGS in the Preventing Toxicity in Immunotherapy conference on May 2nd, 2017. Cell Design Labs is working with small molecules to modulate CAR T cells, which would allow clinicians to monitor and prevent toxicity issues in cancer treatment. For more information, please visit http://www.PEGSummit.com/Immunotherapy/

Megan Allyse, Ph.D., Assistant Professor, Biomedical Ethics, The Mayo Clinic spoke to CHI to discuss the ethical implications that come with advancing NIPT technology, from informed consent and proper infrastructure to proper education for clinicians. She also speaks on how NIPT can serve the larger field of molecular diagnostics to understand what widespread translation looks like for precision medicine technologies. Dr. Allyse is speaking at the NIPT: What’s Next in Technology Development short course, taking place February 20, 2017 in San Francisco as part of the Molecular Med Tri-Conference. For details, visit http://www.TriConference.com/

Philip Arlen from Precision Biologics recently spoke with CHI. He will be speaking at PEGS in the Adoptive T Cell Therapy conference on May 3rd 2017. Precision Biologics is working with cancer vaccines to develop personalized cancer treatments that target tumors without damaging healthy human tissues. For more information, please visit http://www.PEGSummit.com/TCellTherapy/

Abhijit Patel of the Yale University School of Medicine recently spoke with CHI, on February 23, 2017 he will be speaking during the Circulating Cell-Free DNA Symposium at Molecular Medicine Tri-Conference. As a physician-scientist, Dr. Patel maintains an active clinical radiation oncology practice. His research group at Yale is working to develop and clinically validate novel noninvasive DNA- and RNA-based cancer diagnostics. In this podcast, Dr. Patel spoke to CHI to discuss the emerging technologies and challenges in liquid biopsy including developing robust and sensitive assays to detect early stage disease. For more information, please visit http://www.TriConference.com/Circulating-DNA/

Kent Simmons of CHI speaks with Dr. Tim Whitehead, Assistant Professor of Chemical Engineering and Materials Science at Michigan State University About his upcoming keynote presentation “Programming Proteins by Deep Sequencing and Design” at PEGS Boston 2017. For more information, please visit http://www.PEGSummit.com/Immunogenicity-Mitigation/

G. Elisabeta Marai, Ph.D., Associate Professor, Electronic Visualization Lab, University of Illinois spoke to CHI to discuss her work in developing scalable systems for visual analysis on large-display environments, the inspiration behind the project, and how BactoGeNIE works today. She also discusses future challenges in displaying and visualizing large sets of bioinformatics data. Dr. Marai is speaking at the Data Visualization & Exploration Tools conference, taking place May 23-25, 2017 in Boston as part of the Bio-IT World Conference & Expo. For details, visit http://www.Bio-ITWorldExpo.com/Data-Visualization/

Dr. Kfir Oved outlines some of the greatest obstacles to controlling antibiotic misuse, advice for introducing new products in the clinical setting, describes some of the most exciting new developments emerging for AMR, and summarizes what he is looking forward to at the Advanced Diagnostics for Infectious Disease track at Molecular Diagnostics Europe Summit. For more information, please visit http://www.MolecularDXEurope.com/Infectious-Disease-Dx/

Dr. Bert Niesters discusses how standard practice in the emergency room setting has changed for both care delivered and spread of infection, the challenges associated with giving results rapidly and impact on the cost of care. He outlines improvements in their own system in emergency room care and plans for the future, and also talks about what he is looking forward to at the Point-of-Care Diagnostics track at Molecular Diagnostics Europe Summit. For more information, please visit http://www.MolecularDXEurope.com/Point-of-Care-Dx/

John Mattison of Kaiser Permanente speaks to CHI on November, 14, 2016. Dr. Mattison will be chairman at the Bioinformatics track during the Molecular Medicine Triconference, February 19 - 24, in San Francisco, CA. Topics include discussing the current state of bio-informatics and the large influx of information, as well as how to decide what information is pertinent with regards to which diseases. The talk concludes with his excitement to see how others are progressing along this topic as well. For more information, please visit http://www.TriConference.com/Bioinformatics-Big-Data/